These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29912633)

  • 21. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
    Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
    Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
    Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
    Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
    Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells.
    Zhang F; Zhang H; Wang Z; Yu M; Tian R; Ji W; Yang Y; Niu R
    Biochem Pharmacol; 2014 Jan; 87(2):292-302. PubMed ID: 24239898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
    Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
    J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
    Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
    Shetty PK; Thamake SI; Biswas S; Johansson SL; Vishwanatha JK
    PLoS One; 2012; 7(9):e44299. PubMed ID: 22957061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway.
    Zhang F; Wang Z; Yuan J; Wei X; Tian R; Niu R
    Breast Cancer Res Treat; 2015 Sep; 153(2):263-75. PubMed ID: 26253946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5α-Epoxyalantolactone Inhibits Metastasis of Triple-Negative Breast Cancer Cells by Covalently Binding a Conserved Cysteine of Annexin A2.
    Wei M; Zhou Y; Li C; Yang Y; Liu T; Liu Y; Wei Y; Liu N; Liu S; Wang Q; Cao S; Sun Y; Sheng P; Lu C; Yang C; Liu X; Yang G
    J Med Chem; 2021 Sep; 64(17):12537-12547. PubMed ID: 34351142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ANXA2 expression in African American triple-negative breast cancer patients.
    Gibbs LD; Chaudhary P; Mansheim K; Hare RJ; Mantsch RA; Vishwanatha JK
    Breast Cancer Res Treat; 2019 Feb; 174(1):113-120. PubMed ID: 30478786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
    Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.
    Chaudhary P; Gibbs LD; Maji S; Lewis CM; Suzuki S; Vishwanatha JK
    Breast Cancer Res; 2020 Jan; 22(1):11. PubMed ID: 31992335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.
    Kpetemey M; Dasgupta S; Rajendiran S; Das S; Gibbs LD; Shetty P; Gryczynski Z; Vishwanatha JK
    Mol Cancer; 2015 Aug; 14():156. PubMed ID: 26272794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
    Anborgh PH; Lee DJ; Stam PF; Tuck AB; Chambers AF
    Expert Opin Ther Targets; 2018 Aug; 22(8):727-734. PubMed ID: 30025479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
    Taurin S; Rosengren RJ
    Med Oncol; 2022 Dec; 40(1):45. PubMed ID: 36494506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.